Table 4.
Pharmacokinetics of Cytarabine and Daunorubicin Following CPX-351 (101 units/m2, day 5)
| Variable | Cmax(ng/mL) | tmax(hours) | AUC(0-τ)(ng·hr/mL) | t1/2(hours) | CL (mL/h/m2) |
|---|---|---|---|---|---|
| Cytarabine | |||||
| No. of patients | 13 | 13 | 13 | 13 | 13 |
| Median | 55,800 | 2 | 1,487,638 | 31.1 | 67.9 |
| Mean | 64,608 | 3.02 | 1,851,089 | 36.9 | 67.3 |
| SD | 23,230 | 2.25 | 934,523 | 24.5 | 30.6 |
| Daunorubicin | |||||
| No. of patients | 13 | 13 | 13 | 13 | 13 |
| Median | 29,200 | 2 | 633,579 | 21.9 | 70.1 |
| Mean | 30,185 | 1.87 | 666,640 | 25.2 | 72.9 |
| SD | 6,198 | 0.74 | 209,198 | 11.6 | 23 |
Abbreviations: Cmax, maximum serum concentration; tmax, time to maximum serum concentration; AUC(0-τ), area under the serum concentration-time curve from time 0 to time τ (end of the dosing interval); t1/2, terminal half-life; CL, clearance; SD, standard deviation.